Janus Henderson Group’s Soleno Therapeutics SLNO Stock Holding History

Janus Henderson Group’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$238M	Sell	7,099,328 -79,026	-1%	-$3.1M	0.11%	176
2025 Q4	$332M	Buy	7,178,354 +1,122,015	+19%	+$61.5M	0.15%	146
2025 Q3	$409M	Buy	6,056,339 +748,330	+14%	+$55.5M	0.19%	114
2025 Q2	$445M	Buy	5,308,009 +167,110	+3%	+$12.5M	0.22%	111
2025 Q1	$370M	Sell	5,140,899 -47,366	-0.9%	-$2.31M	0.2%	122
2024 Q4	$233M	Buy	5,188,265 +1,107,166	+27%	+$57.4M	0.12%	176
2024 Q3	$206M	Buy	4,081,099 +722,226	+22%	+$34.6M	0.11%	187
2024 Q2	$137M	Buy	3,358,873 +488,062	+17%	+$20.7M	0.07%	223
2024 Q1	$123M	Buy	2,870,811 +346,914	+14%	+$15.7M	0.07%	239
2023 Q4	$102M	Buy	2,523,897 +319,844	+15%	+$9.1M	0.06%	249
2023 Q3	$65M	Buy	+2,204,053	New	+$13.3M	0.04%	313

Other funds holding SLNO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Janus Henderson Group's SLNO Position: Q1 2026 in Review

Janus Henderson Group reduced its Soleno Therapeutics (SLNO) stake by 1.1% in Q1 2026, selling an estimated $3.1M and leaving 7,099,328 shares worth $238M. The position accounts for 0.11% of the portfolio, ranked #176.

Janus Henderson Group first reported a position in SLNO in Q3 2023 and has held it in 11 quarters since. The position peaked at $445M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

Janus Henderson Group held 7,099,328 shares of Soleno Therapeutics worth $238M as of Q1 2026.
Janus Henderson Group sold 79,026 Soleno Therapeutics shares in Q1 2026, an estimated $3.1M.
Soleno Therapeutics made up 0.11% of Janus Henderson Group's portfolio in Q1 2026, its #176 holding.
Janus Henderson Group first reported a position in Soleno Therapeutics in Q3 2023 and has held it in 11 quarters since.
Janus Henderson Group's Soleno Therapeutics position peaked at $445M in Q2 2025.
225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.